With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
In the US, each year over 1.4 million people will be hospitalized for unstable angina (UA) and non-ST-segment-elevation myocardial infarction (NSTEMI). Multiple antiplatelet agents have been developed to interfere with or inhibit the specific pathways of platelet activation and aggregation that lead to the development of UA and NSTEMI. Join Drs Newby, Popma, and Wiviot as they discuss.
Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.
Described as a "fish tale with growing credibility," the authors of a new review cite mounting data in support of the many cardiovascular benefits of omega-3 fatty acids.
The treatment options for oral anticoagulation therapy are constantly evolving. Join our expert panel, Drs. Graham Turpie, Jessica L. Mega, Jeffrey Weitz, as they discuss the new data and clinical implications of new anticoagulant medications for patients with ACS
As innovative research expands and unfolds, management of the patient with acute coronary syndrome continually takes on new dimensions. Join Dr. Eugene Braunwald and other experts as they delve into current and future pharmacotherapeutic strategies and issues surrounding the best practices for ACS patients.
Recently published data suggest that prior polyvascular disease increases the risk for inhospital adverse events in patients with ACS. Join Drs. Deepak Bhatt, Jean-Pierre Bassand, and José R. Gonzalez-Juanatey for a discussion of the current data on identification and management of patients with polyvascular disease.
AF can lead to stroke, congestive heart failure, and other serious complications. Successful management should include reducing these risks. Join our expert panel, Drs. Peter Rothwell, Donald Easton, and Mark Alberts, as they discuss new data and strategies for improving outcomes in patients with AF.
Despite modern therapy, the rates of death, MI, bleeding, and readmission remain high in patients with ACS. Join Drs. Jeffery Popma, Héctor Bueno, Freek Verheugt, and Sunil. Rao for a review of the latest data on antiplatelet therapy for patients with ACS.
How can we reduce the time taken to accurately diagnose ACS? ECGs and biomarkers may be nondiagnostic, even the presenting symptoms can vary or be absent. As every 30 minutes delay is associated with a 7.5% relative increase in mortality, time is indeed muscle. Join Drs. Gibson, Pride, Santini, and Krucoff as they present new insights into this complex field.
Join Drs. Harrington, Gibson, and Bates as they discuss the difficult issues of antithrombotic choices and the medical management of patients with NSTEMI.
Atrial fibrillation (AF) is the most frequently occurring cardiac arrhythmia affecting some 2.2 million Americans with often serious clinical consequences.. Join Drs. Bhatt, Connolly and Camm for a discussion on the risk factors, management challenges, and new data on treatment options for patients with AF
Several recent studies have demonstrated that patients with atherothrombosis who experience bleeding may be at increased risk for long-term adverse ischemic events. Whereas the specific mechanism(s) that may explain the correlation between bleeding and ischemic events remains to be fully elucidated, these findings may have important ramifications for the selection of appropriate antiplatelet therapy. Drs. Berger, Mehta, Simon, Steg, and White discuss.
Harmonizing guideline recommendations for antiplatelet therapy with recent clinical trial data and concerns about bleeding can pose a challenge. Drs Berger, Mehta, Simon, Steg, and White each give presentations addressing issues relating to the appropriate use of antiplatelet therapy in patients with atherothrombotic disease
This program will examine the importance of acute and long-term dual antiplatelet therapy to protect ACS patients against thrombotic events. It will also provide information on established treatment guidelines and pivotal evidence-based clinical trial results arising from head-to-head comparisons of antiplatelet treatment options.
Warfarin remains the cornerstone of stroke prevention in patients with AF. However, many patients are unable or unwilling to take it. Could antiplatelet therapy fill this gap? How might investigational anticoagulants change the playing field? Dr Naccarelli leads a panel discussion with Drs Connolly and Camm.
One-year data from the HORIZONS-AMI showed significant reductions in the incidence of cardiac-related death as well all-cause mortality. Join Drs Montalescot, Bode, Guagliumi, as they summarize the impact of the trial for the French, German and Italian cardiologist.
Balancing antithrombotic efficacy with risk of bleeding: Join our international panel of experts, Steen Husted, José Carlos Nicolau, Sunil Rao and Robert Storey as they review the mechanisms of platelet activation and emerging evidence from ongoing studies to novel antiplatelet therapies.
